Publicaciones en colaboración con investigadores/as de NewYork–Presbyterian Hospital (8)

2019

  1. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma

    Blood, Vol. 133, Núm. 18, pp. 1953-1963

2010

  1. Monoclonal gammopathy of undetermined significance: A consensus statement: Guideline

    British Journal of Haematology, Vol. 150, Núm. 1, pp. 28-38

2009

  1. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline

    British Journal of Haematology, Vol. 144, Núm. 6, pp. 895-903

2008

  1. Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: Results from the APEX study

    British Journal of Haematology, Vol. 143, Núm. 4, pp. 511-519

  2. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma

    British Journal of Haematology, Vol. 143, Núm. 2, pp. 222-229

2007

  1. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial

    Blood, Vol. 110, Núm. 10, pp. 3557-3560

  2. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma

    British Journal of Haematology, Vol. 137, Núm. 5, pp. 429-435

2005

  1. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

    New England Journal of Medicine, Vol. 352, Núm. 24, pp. 2487-2498